

Item 5.07 Submission of Matters to a Vote of Security Holders.

On May 23, 2016, the Company held its Annual Meeting of Stockholders. A total of 17,203,677 shares of common stock were present in person or represented by proxy at the meeting, representing approximately 86.7% percent of the Company's outstanding common stock as of the March 24, 2016 record date. The following are the voting results for the proposals considered and voted upon at the meeting, all of which were described in the Company's Definitive Proxy Statement filed with the Securities and Exchange Commission on April 8, 2016.

PROPOSAL 1 - Election of Director. As to the election of director nominee, Richard Chin, M.D., to serve as a Class III director until the 2019 annual meeting of stockholders and until his successor is duly elected and qualified, the voting was as follows:

| | Votes FOR | Votes WITHHELD | Broker Non-Votes |
|-----------------------|------------|----------------|------------------|
| 1. Richard Chin, M.D. | 13,435,821 | 592,759 | 3,175,097 |

PROSPOAL 2 - Approval of Kindred Biosciences, Inc. 2016 Equity Incentive Plan. As to the proposal to approve the Kindred Biosciences, Inc. 2016 Equity Incentive Plan, the voting was as follows:

| | Votes FOR | Votes AGAINST | Votes ABSTAINED | Broker Non-Votes |
|--|------------|---------------|-----------------|------------------|
| | 10,973,907 | 2,719,830 | 334,843 | 3,175,097 |

PROPOSAL 3 - Ratification of Independent Public Accountant. As to the ratification of the appointment of KMJ Corbin & Company LLP as the Kindred Biosciences, Inc. independent registered public accounting firm for the year ending December 31, 2016, the voting was as follows:

| | Votes FOR | Votes AGAINST | Votes ABSTAINED | Broker Non-Votes |
|--|------------|---------------|-----------------|------------------|
| | 16,854,393 | 16,730 | 332,554 | — |

Based on the forgoing votes, Richard Chin was elected as a Class III director, and Proposal 2 and Proposal 3 were approved.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

KINDRED BIOSCIENCES, INC.

Date: May 27, 2016 By: /s/ Richard Chin
Richard Chin, M.D.
President and Chief Executive Officer